Brooke Harbor Health System
PMHNP Clinical Learning Environment
Condition Guide
Anxiety becomes clinically significant when fear, worry, or avoidance is persistent, disproportionate to the situation, difficult to control, and associated with meaningful distress or impaired functioning. Assessment should identify the specific anxiety pattern while also addressing safety, medical and substance-related contributors, comorbidity, development, and the person's goals.
Clinical application
Apply these prompts within the simulated clinical context. They support—but do not replace—clinical judgment, supervision, consultation, current guidance, local policy, law, or emergency procedures.
Neurobiology
Anxiety involves interacting systems rather than a single pathway. Relevant findings include amygdala hyperreactivity and altered prefrontal regulation of fear circuitry, HPA-axis dysregulation, imbalance across inhibitory GABA and excitatory glutamate signaling, and heightened locus coeruleus–norepinephrine activity. Genetic vulnerability, learning history, stress exposure, and temperamental behavioral inhibition can shape risk and expression.
Epidemiology and Course
Separation anxiety and specific phobias commonly begin in childhood; social anxiety often emerges by adolescence; panic disorder frequently begins in late adolescence or early adulthood; and generalized anxiety may become evident later and follow a fluctuating, chronic course. Depressive disorders are common across anxiety presentations, and alcohol, cannabis, sedatives, or other substances may be used in attempts to manage distress while ultimately worsening symptoms or risk.
Diagnostic Features by Disorder
Anxiety disorders share heightened threat anticipation, autonomic arousal, avoidance, and reinforcement of fear, but the focus and course differ. Normal anxiety is generally proportionate, time-limited, and compatible with adaptive action. Clinically significant anxiety persists beyond the expected context, produces avoidance or safety behaviors, and causes meaningful distress or impairment.
Excessive anxiety and worry occur across multiple life areas on more days than not for at least six months and are difficult to control. Adults also have at least three associated symptoms, such as restlessness, fatigue, concentration difficulty, irritability, muscle tension, or disturbed sleep; only one is required in children. Symptoms must cause clinically meaningful distress or impairment.
Recurrent, unexpected panic attacks are followed by at least one month of persistent concern about additional attacks or their consequences, or by maladaptive behavioral change such as avoidance. Panic attacks may occur in many conditions; the unexpected and persistent aftermath defines panic disorder.
Marked fear centers on social situations in which scrutiny or negative evaluation is possible. The situations almost always provoke fear and are avoided or endured with intense distress. The response is disproportionate, persists for at least six months, and causes meaningful distress or impairment.
A particular object or situation reliably produces immediate fear and is avoided or endured with intense distress. The fear is disproportionate to actual danger and sociocultural context, persists for at least six months, and impairs functioning or causes significant distress.
Marked fear involves at least two types of situations—public transportation, open spaces, enclosed places, crowds or lines, or being outside the home alone—because escape or help may be difficult if panic-like or incapacitating symptoms occur. Avoidance or companion dependence persists for at least six months and causes significant distress or impairment.
Developmentally inappropriate and excessive fear concerns separation from major attachment figures, with at least three characteristic symptoms involving anticipated harm, refusal, distress, nightmares, or physical complaints. The pattern lasts at least four weeks in children and adolescents and typically at least six months in adults, with clinically meaningful distress or impairment.
Rating Scales & Screening Tools
Screening and severity measures can identify symptoms, establish a baseline, and track change over time. They do not establish an anxiety-disorder diagnosis or determine whether symptoms are better explained by another psychiatric condition, a substance, a medication, or a medical illness. For administration and interpretation guidance, see the Toolbox's Rating Scales & Screening.
Seven-item self-report measure of generalized anxiety symptoms during the previous two weeks. It is useful for initial screening and repeated severity monitoring, but its items also occur in other anxiety, mood, trauma-related, and medical presentations.
Access the instrument and scoring information ↗
Five-item transdiagnostic measure covering anxiety frequency, intensity, avoidance, interference with work or school, and interference with social functioning. Useful when anxiety crosses diagnostic categories.
Access the self-report instrument ↗
Seven-item measure of panic frequency, panic-related distress, anticipatory anxiety, agoraphobic and interoceptive avoidance, and functional impairment during the previous week. Best used when panic disorder is suspected or established.
Access the SPIN ↗ · Access the LSAS ↗
The self-rated SPIN assesses fear, avoidance, and physiologic discomfort. The LSAS examines fear and avoidance across social-interaction and performance situations. Use either to support—not replace—a diagnostic interview for social anxiety disorder.
Access child and parent forms ↗
Youth- and caregiver-report forms screen for pediatric anxiety symptoms across generalized anxiety, separation anxiety, panic or somatic symptoms, social anxiety, and school avoidance. Interpret discrepancies between reporters as clinically meaningful information.
Access child, parent, and preschool forms ↗
Developmentally tailored forms assess several childhood anxiety domains and can support baseline measurement and treatment monitoring. Select the form appropriate to the child's age and reporter.
Relevant Medication Classes
Medication is one component of treatment and should be paired with ongoing assessment of benefit, adverse effects, adherence, functional recovery, and access to psychotherapy. For practical support with actual-use histories, interactions, and monitoring, see the Toolbox's Medication Reconciliation & Monitoring.
First-line medication options for most anxiety disorders; begin thoughtfully, monitor early activation and tolerability, and allow an adequate trial.
Venlafaxine and duloxetine are evidence-supported options for selected anxiety disorders; monitor blood pressure, adverse effects, and discontinuation symptoms.
A non-benzodiazepine alternative or adjunct for GAD; it requires scheduled dosing and is not an immediate-relief medication.
May help with short-term or situational symptoms; consider sedation, anticholinergic burden, cardiac risk, and effects on driving or work.
Sometimes used for circumscribed performance-related autonomic symptoms; assess asthma, bradycardia, hypotension, and other contraindications.
Has evidence for GAD and is used off-label for this purpose in the United States; consider sedation, misuse potential, renal dosing, and withdrawal effects.
Reserve for carefully selected short-term or bridge use because tolerance, dependence, withdrawal, falls, cognitive effects, and dangerous co-use can outweigh benefit.
Older alternatives with evidence in panic disorder; anticholinergic effects, orthostasis, cardiac conduction concerns, and overdose toxicity limit routine use.
Relevant Psychotherapy Modalities
Psychotherapy selection should reflect the specific anxiety disorder, developmental context, patient preference, readiness, access, and clinician competence. For a broader comparison of approaches, see the Toolbox's Psychotherapy Modalities.
First-line across anxiety disorders; addresses threat appraisal, avoidance, safety behaviors, and skills for managing physical and cognitive symptoms.
Graduated, repeated exposure is central for specific phobia, panic, agoraphobia, and social anxiety. Exposure and response prevention principles help interrupt avoidance and reassurance cycles.
Builds psychological flexibility by helping patients make values-guided choices while allowing uncomfortable thoughts and sensations to be present.
May explore recurring relational patterns, conflicts, meanings, and defenses associated with anxiety when this approach fits the formulation and patient preference.
Particularly relevant for childhood-onset anxiety when accommodation, reassurance, separation patterns, or family stress maintain symptoms or limit exposure practice.
Clinical Practice Guidelines
No current APA or VA/DoD guideline specifically covers this full group of anxiety disorders. The following authoritative guidance addresses major adult and pediatric anxiety presentations.
Recognition and management of generalized anxiety disorder and panic disorder in adults; published in 2011 and updated in 2020.
Recognition, assessment, and treatment of social anxiety disorder across children, young people, and adults; minor updates were made in 2024.
Quality statements for identifying, treating, and monitoring anxiety disorders across age groups and care settings.
Evidence-based assessment and treatment guidance for children and adolescents with anxiety disorders, published in 2020.
Related Resources
Plan targeted evaluation when symptoms, onset, vital signs, exposures, or examination findings suggest a medical or substance-related contributor.
Use when severe panic, suicidality, intoxication or withdrawal, inability to function, or another acute presentation requires stabilization and disposition planning.
Apply developmentally informed assessment, caregiver and school collateral, assent, confidentiality, and pediatric treatment considerations.